Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective June 18, 2009, the NIKE, Inc. (the "Company") Board of Directors appointed Dr. John C. Lechleiter to serve as a Director of the Company.

John C. Lechleiter, Ph.D, 55, is chairman of the board, president, and chief executive officer of Eli Lilly and Company ("Lilly"). Dr. Lechleiter joined Lilly in 1979 as a senior organic chemist in the process research and development division, and has held management positions in England and the U.S. He was named vice president of pharmaceutical product development in 1993 and vice president of regulatory affairs in 1994. In 1996, he was named vice president for development and regulatory affairs. Dr. Lechleiter became senior vice president of pharmaceutical products in 1998, and executive vice president of pharmaceutical products and corporate development in 2001. He was named executive vice president of pharmaceutical operations in 2004. Dr. Lechleiter was appointed president and chief operating officer of Lilly in 2005, when he also joined Lilly's board of directors. He was named president and chief executive officer in April 2008 and became chairman on January 1, 2009.

There was no arrangement or understanding pursuant to which Dr. Lechleiter was elected as a director, and there are no related party transactions between the Company and Dr. Lechleiter. Dr. Lechleiter will serve on the Company's Compensation Committee and the Corporate Responsibility Committee.

The Company issued a press release on June 18, 2009 announcing the appointment of Dr. Lechleiter. The press release is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

The following exhibits are being furnished with this Current Report on Form 8-K:

Exhibit 99.1 Press Release dated June 18, 2009.